These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 6525083)

  • 21. A multicentred phase III comparative clinical trial of Mesigyna, Cyclofem and Injectable No. 1 given by intramuscular injection to Chinese women. II. The comparison of bleeding patterns.
    Sang GW; Shao QX; Ge RS; Ge JL; Chen JK; Song S; Fang KJ; He ML; Luo SY; Chen SF
    Contraception; 1995 Mar; 51(3):185-92. PubMed ID: 7621686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of norethisterone enanthate on endometrial bleeding and changes in coagulation function, ovarian hormones and endometrial histology in Thai women.
    Meng YX; Virutamasen P
    Contraception; 1991 Jul; 44(1):73-82. PubMed ID: 1893702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I clinical trial of two contraceptive preparations. Norethisterone enanthate (NEN) and norethisterone acetate (NET).
    Andino N
    Contraception; 1981 Feb; 23(2):141-55. PubMed ID: 6786825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of different doses of norethisterone oenanthate.
    Fotherby K; Hamawi A; Howard G; Bye PG; Elder M
    Contraception; 1984 Apr; 29(4):325-33. PubMed ID: 6744856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum levels of norethisterone, estradiol and progesterone after administration of norethisterone oenanthate at different sites: a cross-over study.
    Virutamasen P; Dhanapas S; Leepipatpaiboon S
    Asia Oceania J Obstet Gynaecol; 1987 Mar; 13(1):49-53. PubMed ID: 3593083
    [No Abstract]   [Full Text] [Related]  

  • 26. Reduction of the oral contraceptive estrogen burden by alternate day estrogen administration.
    Segre EJ; Henzl MR; Giner J; Scheel C; Bessler S
    Contraception; 1975 Aug; 12(2):155-74. PubMed ID: 1139955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New long-acting injectable microcapsule contraceptive system.
    Beck LR; Cowsar DR; Lewis DH; Gibson JW; Flowers CE
    Am J Obstet Gynecol; 1979 Oct; 135(3):419-26. PubMed ID: 114054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaginal bleeding patterns in women using once-a-month injectable contraceptives.
    Fraser IS
    Contraception; 1994 Apr; 49(4):399-420. PubMed ID: 8013222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Norethisterone levels in maternal serum and milk after intramuscular injection of norethisterone oenanthate as a contraceptive.
    Fotherby K; Towobola O; Muggeridge J; Elder MG
    Contraception; 1983 Nov; 28(5):405-11. PubMed ID: 6673900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I comparative clinical trial with subdermal implants--bioabsorbable levonorgestrel or norethisterone pellet fused with cholesterol.
    Joshi UM; Joshi JV; Donde UM; Sankoli GM; Virkar KD; Saxena BN
    Contraception; 1985 Jan; 31(1):71-82. PubMed ID: 3921309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Return to ovulation following the use of long-acting injectable contraceptives: a comparative study.
    Garza-Flores J; Cardenas S; Rodríguez V; Cravioto MC; Diaz-Sanchez V; Perez-Palacios G
    Contraception; 1985 Apr; 31(4):361-6. PubMed ID: 3159544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Some metabolic effects of long-term use of the injectable contraceptive norethisterone oenanthate.
    Howard G; Blair M; Fotherby K; Trayner I; Hamawi A; Elder MG
    Lancet; 1982 Feb; 1(8269):423-5. PubMed ID: 6121092
    [No Abstract]   [Full Text] [Related]  

  • 33. Use of Anovlar in gynaecological disorders and contraception.
    Shahani SM; Chiklikar A
    J Obstet Gynaecol India; 1968 Apr; 18(2):592-7. PubMed ID: 12331827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical experience with intramuscular norethisterone oenanthate as a contraceptive.
    Howard G; Blair M; Fotherby K; Howell R; Elder MG; Bye P
    J Obstet Gynaecol (Lahore); 1980; 1(1):53-8. PubMed ID: 12264797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical evaluation of injectable biodegradable contraceptive system.
    Beck LR; Ramos RA; Flowers CE; Lopez GZ; Lewis DH; Cowsar DR
    Am J Obstet Gynecol; 1981 Aug; 140(7):799-806. PubMed ID: 7020421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a low-dose monthly injectable contraceptive system: I. Choice of compounds, dose and administration route.
    Garza-Flores J; Diaz-Sanchez V; Jimenez-Thomas S; Rudel HW
    Contraception; 1984 Oct; 30(4):371-9. PubMed ID: 6509988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contraceptive efficacy of norethindrone encapsulated in injectable biodegradable poly-dl-lactide-co-glycolide microspheres: phase II clinical study.
    Singh M; Saxena BB; Graver R; Ledger WJ
    Fertil Steril; 1989 Dec; 52(6):973-80. PubMed ID: 2591574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase IV study of the injection Norigest in Pakistan.
    Kazi A; Holck SE; Diethelm P
    Contraception; 1985 Oct; 32(4):395-403. PubMed ID: 3907968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The contraceptive efficacy of 10mg or 25mg of norethindrone given orally on day 15-22 of the human menstrual cycle.
    Nygren KG; Johansson ED; Wide L
    Contraception; 1974 Mar; 9(3):249-56. PubMed ID: 4442274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of two triphasic oral contraceptives containing either gestodene or norethindrone: a randomized, controlled trial.
    Weber-Diehl F; Lehnert J; Lachnit U
    Contraception; 1993 Oct; 48(4):291-301. PubMed ID: 8222658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.